Navigation Links
Ovalum Ltd. Received Clearance to Market the CiTop™ Product-Line in Israel
Date:7/10/2008

Following FDA clearance and CE approval, revolutionary CiTop™ product-line is now available in Israel. Ovalum Ltd., a privately held Israeli medical device company, has announced today the clearance to market of its unique CiTop™ product-line in Israel.

Rehovot, Israel (PRWEB) July 10, 2008 -- Ovalum Ltd., a privately held Israeli medical device company, has announced today the clearance to market of its unique CiTop™ product-line in Israel. These products are indicated for traversing arterial obstructions, including chronic total occlusions, to allow blood flow through the vasculature.

Dr. Alexander Belenky, Head of Interventional Radiology Unit at Rabin Medical Center and chief Radiologist at Assuta Tel-Aviv Medical Center says: "This unique technology greatly assists in rescuing limbs which could not be treated by any other means. Opening an occluded artery is a must for saving the limb from amputation. The CiTop(tm) Guidewire System is crossing these occlusions in tremendous ease even in the most complicated cases".

According to Barry T. Katzen, MD, FACR, FACC, a member of Ovalum Ltd. Advisory Board and medical director of Baptist Cardiac and Vascular Institute in Miami, "Saving limbs is dependent on successful recanalization of total occlusions, frequently in long segments. This device is a simple and effective method in the hands of the physician to improve results in the treatment of total occlusions".

Chronic Total Occlusion (CTO) is one of the main challenges that Interventional Cardiologists and Radiologists are facing today. Ovalum's CTO solution, the CiTop™ Guidewire technology enables the minimally invasive intervention specialists to cross over the arterial blockage in a controllable and reproducible way. The system is made of a highly flexible guidewire body and a distal tip consisting of a working element with dilating capabilities to facilitate wire cross-over. The CiTop™ product-line also includes the 0.014" CoBra™ CTO Guidewire and the TraVerse™ Micro-catheter.

About Ovalum

Ovalum Ltd. was founded in March 2005 by Noam Shamay and Eitan Finkelstein. Located in Rabin Science Park Rehovot, Israel. OVALUM Ltd. develops, manufactures and markets breakthrough products for the minimally invasive cardiology and interventional radiology markets designed specifically for the most challenging arterial procedures

Ovalum Ltd. investors: Ziegler Meditech equity Partners LP and Smithfield Fiduciary LLC, represented by Eitan Machover (Director) and Pontifax LP represented by Tomer Kariv (Director).

CiTop™, CoBra™, TraVerse™ are all trademarks of Ovalum Ltd.

###


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe
2. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
3. WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
4. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
5. Pharmacyclics Announces It Received Nasdaq Notification
6. BioDuro & The National Center for Safety Evaluation of Drugs Received Full AAALAC Accreditation
7. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
8. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
9. YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL
10. MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System
11. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for TenoMend(TM) Collagen Tendon Wrap for the Management and Protection of Tendon Injuries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Surgical Wound Market with the addition of its newest module, US Hemostats & ... market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
Breaking Biology News(10 mins):